Precision mass spectrometry testing.
Nationwide services.
Major and rare disease diagnosis.
Guides treatment and clinical decisions.
Advancing public health and precision medicine.
Our center is the first laboratory in Taiwan to introduce mass spectrometry technology into clinical testing, establishing a comprehensive and diverse clinical mass spectrometry platform with the highest testing capacity nationwide. For 22 consecutive years, our team has passed CAP international accreditation and has also obtained certifications from the Ministry of Labor and the Ministry of Health and Welfare, earning strong recognition for our testing quality and technical expertise. We have long been committed to the clinical application and innovative development of mass spectrometry platforms. In response to the needs of the semiconductor industry, we pioneered the development of indium and zirconium heavy metal testing, serving as important indicators for early exposure risk monitoring. In line with the trend of precision and personalized medicine, we utilize LC-MS/MS to establish therapeutic drug monitoring for immunosuppression medications, helping improve transplant patient survival rates. We also uniquely developed uremic toxin testing, overcoming the limitations of traditional clinical testing restricted by commercial reagents. In addition, we provide a wide range of services including therapeutic drug monitoring, drug abuse testing, rare disease screening, hormone and metabolite analysis, as well as amino acid and nutritional assessments. With nationwide testing services, our center demonstrates its leading position in clinical mass spectrometry diagnostics.
Pioneered the application of mass spectrometry technology in therapeutic drug monitoring, overcoming the limitations of traditional immunoassays and significantly enhancing the accuracy of dosage adjustment and the quality of clinical decision-making.
Possesses the capability to independently develop testing items, integrating clinical practice needs to continuously innovate and expand diverse heavy metal testing as well as diagnostics for rare diseases such as Fabry disease. Established a comprehensive amino acid and metabolomics testing platform to support personalized health management through precise diagnostics, fulfilling social responsibility and ESG sustainability commitments.
25 years of clinical excellence, leading in mass spectrometry.
Over 80,000 tests annually, growing strong at 10.6%.
98 mass spectrometry services, nationwide coverage.
15,396 screened for rare diseases, 32 confirmed cases.
Assisted in the diagnosis of 20 cases of porphyria.
In 2000, pioneered the application of ICP-MS in clinical heavy metal testing.
In 2012, took the lead in introducing LC-MS/MS for small molecule testing.
In 2014, first applied mass spectrometry technology to therapeutic drug monitoring for immunosuppression medications.
In 2017, exclusively developed IS/PCS nephrotoxin testing.
In 2020, became the world’s first to develop indium and zirconium heavy metal testing programs.
22 years of consecutive CAP accreditation.
Designated by the Ministry of Labor for Specialized Health Examinations.
Certified by TFDA for Drug Abuse Urine Testing.
Awarded 1 silver and 2 bronze in evidence-based clinical applications.
The satisfaction rate in the survey reached 99.3%.
Undertook domestic and international training and visits in mass spectrometry testing technology.
The team has published 145 papers related to mass spectrometry and heavy metals.
The highest citation count for a single paper is 98.
15 papers have been cited more than 50 times.
Organized international clinical mass spectrometry conferences.
Introduced mass spectrometry technology into clinical testing, providing nationwide referral services and enhancing testing quality.
Established precise therapeutic drug monitoring to improve patient survival rates and care outcomes.
Pioneered diverse heavy metal testing to strengthen early exposure risk monitoring.
Developed rare disease screening methods to protect vulnerable populations, fulfilling social responsibility and sustainability commitments.
In response to an aging society, established a comprehensive amino acid and nutrition assessment platform to support personalized health management.
